MIUDELLA® is a strategic addition to Organon’s portfolio, strengthening its long‑term commitment to advancing women’s health JERSEY CITY, N.J., February 23, 2026 — Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that it has entered into an agreement to exclusively… Read more »
DFW Completes Sale of Sev1Tech to ERT, a Macquarie Capital-backed company DFW Capital Partners (“DFW”) is pleased to announce that it has completed the sale of its portfolio company, Sev1Tech (“Sev1Tech”, or the “Company”) to ERT, a Macquarie Capital-backed company. Sev1Tech is a provider of IT modernization, cloud, cybersecurity, engineering, training and program support services… Read more »
DFW Capital Partners announced today that Patrick Fairfield has been promoted to Principal. Fairfield joined DFW in 2017 as an Associate and has advanced through roles of increasing responsibility, earning his promotion through strong performance and leadership across the firm’s investment activities. In his new role, Fairfield will continue to play a key part in… Read more »
Acquisition Broadens B&A’s Intelligence Capabilities and Strengthens its Position as a Growing National Security Partner McLean, Va., January 13, 2026 – B&A, a leading information technology systems integrator serving the federal government, today announced it has acquired Celestar Corporation, a global, multi-disciplinary intelligence services and solutions provider. Celestar provides specialized intelligence and analytic support to… Read more »
Key Highlights: Sebela Pharmaceuticals® submitted its New Drug Application (NDA) for tegoprazan on January 9, 2026. The NDA seeks approval for three indications: Non-Erosive Reflux Disease (NERD), Erosive Esophagitis (EE) Healing, and EE Maintenance Once approved, tegoprazan will be the first Potassium-Competitive Acid Blocker (P-CAB) to demonstrate superiority in EE healing across all severity grades (LA… Read more »